FDA Generic-Drug Fee Plan Stalled in Budget Impasse

A $300 million program to expedite U.S. reviews of generic drugs made by Mylan, Teva Pharmaceutical Industries and other companies may not start on Oct. 1 as planned because of a budget impasse in Congress.